Cargando…
Emerging pharmaceutical therapies for COPD
COPD, for which cigarette smoking is the major risk factor, remains a worldwide burden. Current therapies provide only limited short-term benefit and fail to halt progression. A variety of potential therapeutic targets are currently being investigated, including COPD-related proinflammatory mediator...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531723/ https://www.ncbi.nlm.nih.gov/pubmed/28790817 http://dx.doi.org/10.2147/COPD.S121416 |
_version_ | 1783253397955149824 |
---|---|
author | Lakshmi, Sowmya P Reddy, Aravind T Reddy, Raju C |
author_facet | Lakshmi, Sowmya P Reddy, Aravind T Reddy, Raju C |
author_sort | Lakshmi, Sowmya P |
collection | PubMed |
description | COPD, for which cigarette smoking is the major risk factor, remains a worldwide burden. Current therapies provide only limited short-term benefit and fail to halt progression. A variety of potential therapeutic targets are currently being investigated, including COPD-related proinflammatory mediators and signaling pathways. Other investigational compounds target specific aspects or complications of COPD such as mucus hypersecretion and pulmonary hypertension. Although many candidate therapies have shown no significant effects, other emerging therapies have improved lung function, pulmonary hypertension, glucocorticoid sensitivity, and/or the frequency of exacerbations. Among these are compounds that inhibit the CXCR2 receptor, mitogen-activated protein kinase/Src kinase, myristoylated alanine-rich C kinase substrate, selectins, and the endothelin receptor. Activation of certain transcription factors may also be relevant, as a large retrospective cohort study of COPD patients with diabetes found that the peroxisome proliferator-activated receptor γ (PPARγ) agonists rosiglitazone and pioglitazone were associated with reduced COPD exacerbation rate. Notably, several therapies have shown efficacy only in identifiable subgroups of COPD patients, suggesting that subgroup identification may become more important in future treatment strategies. This review summarizes the status of emerging therapeutic pharmaceuticals for COPD and highlights those that appear most promising. |
format | Online Article Text |
id | pubmed-5531723 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-55317232017-08-08 Emerging pharmaceutical therapies for COPD Lakshmi, Sowmya P Reddy, Aravind T Reddy, Raju C Int J Chron Obstruct Pulmon Dis Review COPD, for which cigarette smoking is the major risk factor, remains a worldwide burden. Current therapies provide only limited short-term benefit and fail to halt progression. A variety of potential therapeutic targets are currently being investigated, including COPD-related proinflammatory mediators and signaling pathways. Other investigational compounds target specific aspects or complications of COPD such as mucus hypersecretion and pulmonary hypertension. Although many candidate therapies have shown no significant effects, other emerging therapies have improved lung function, pulmonary hypertension, glucocorticoid sensitivity, and/or the frequency of exacerbations. Among these are compounds that inhibit the CXCR2 receptor, mitogen-activated protein kinase/Src kinase, myristoylated alanine-rich C kinase substrate, selectins, and the endothelin receptor. Activation of certain transcription factors may also be relevant, as a large retrospective cohort study of COPD patients with diabetes found that the peroxisome proliferator-activated receptor γ (PPARγ) agonists rosiglitazone and pioglitazone were associated with reduced COPD exacerbation rate. Notably, several therapies have shown efficacy only in identifiable subgroups of COPD patients, suggesting that subgroup identification may become more important in future treatment strategies. This review summarizes the status of emerging therapeutic pharmaceuticals for COPD and highlights those that appear most promising. Dove Medical Press 2017-07-21 /pmc/articles/PMC5531723/ /pubmed/28790817 http://dx.doi.org/10.2147/COPD.S121416 Text en © 2017 Lakshmi et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Lakshmi, Sowmya P Reddy, Aravind T Reddy, Raju C Emerging pharmaceutical therapies for COPD |
title | Emerging pharmaceutical therapies for COPD |
title_full | Emerging pharmaceutical therapies for COPD |
title_fullStr | Emerging pharmaceutical therapies for COPD |
title_full_unstemmed | Emerging pharmaceutical therapies for COPD |
title_short | Emerging pharmaceutical therapies for COPD |
title_sort | emerging pharmaceutical therapies for copd |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531723/ https://www.ncbi.nlm.nih.gov/pubmed/28790817 http://dx.doi.org/10.2147/COPD.S121416 |
work_keys_str_mv | AT lakshmisowmyap emergingpharmaceuticaltherapiesforcopd AT reddyaravindt emergingpharmaceuticaltherapiesforcopd AT reddyrajuc emergingpharmaceuticaltherapiesforcopd |